SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-011499
Filing Date
2023-02-07
Accepted
2023-02-07 07:43:24
Documents
13
Period of Report
2023-02-06
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm235300d1_8k.htm   iXBRL 8-K 37806
2 EXHIBIT 99.1 tm235300d1_ex99-1.htm EX-99.1 9292
  Complete submission text file 0001104659-23-011499.txt   228506

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fwbi-20230206.xsd EX-101.SCH 3045
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fwbi-20230206_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fwbi-20230206_pre.xml EX-101.PRE 22603
7 EXTRACTED XBRL INSTANCE DOCUMENT tm235300d1_8k_htm.xml XML 3608
Mailing Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431
Business Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431 561-589-7020
First Wave BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 464993860 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 23592790
SIC: 2834 Pharmaceutical Preparations